Drug sensitivity analysis revealed that the expression of PLCG1 and NOD2 was correlated with most drugs’ sensitivity; for example, the higher the expression of PLCG1 and NOD2, the higher the sensitivity of GBM to JW-55 (an effective selective β-catenin inhibitor). This evidence concerns the gene NOD2 and glioblastoma.